Lung Cancer and Trial Updates

View overview page
0:47
The future of amivantamab and lazertinib in EGFR-mutant NSCLC
Byoung Chul Cho • 20 Oct 2023
2:51
Bringing change with TTFields therapy in ovarian cancer
Jalid Sehouli • 21 Oct 2023
1:22
Assessing the efficacy of alectinib versus crizotinib in ALK-positive NSCLC
Marco Tagliamento • 23 Oct 2023
1:55
TROPiCS-03: sacituzumab govitecan as a 2L treatment for ES-SCLC
Andrea Ardizzoni • 23 Oct 2023
1:52
Lurbinectedin in combination with pembrolizumab in relapsed SCLC
Andrea Ardizzoni • 23 Oct 2023
2:36
Unexpected safety data in TREASURE: thoracic radiotherapy with atezolizumab in SCLC
Andrea Ardizzoni • 23 Oct 2023
0:38
Challenges in managing SCLC
Antonio Calles Blanco • 22 Oct 2023
0:52
LUPER: lurbinectedin in combination with pembrolizumab in relapsed SCLC
Antonio Calles Blanco • 22 Oct 2023
1:16
STRESS-LUNG-1: assessing the effect of stress on checkpoint inhibitor efficacy in NSCLC
Fang Wu • 21 Oct 2023
2:14
How does psychological stress affect the efficacy of ICIs in NSCLC?
Fang Wu • 21 Oct 2023
2:38
AZD7789 in NSCLC: safety, efficacy, and ongoing evaluation
Benjamin Besse • 24 Oct 2023
2:50
ADC’s for the treatment of NSCLC
Benjamin Besse • 24 Oct 2023
2:28
Optimal duration of immunotherapy administration for patients with NSCLC
Benjamin Besse • 21 Oct 2023
5:11
DARWIN II: deciphering anti-tumor response & resistance to IO w/ intratumour heterogeneity in NSCLC
Crispin Hiley • 22 Oct 2023
1:27
PAPILLON Phase III primary results: amivantamab + chemo vs chemo in EGFR Exon 20 NSCLC
Nicolas Girard • 21 Oct 2023
2:04
MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib
Antonio Passaro • 22 Oct 2023

The Lung Cancer Channel on VJOncology is supported by Takeda and Novocure.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lung Channel, please contact us .
The content of VJOncology is intended for healthcare professionals